ACADIA Pharmaceuticals (ACAD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ACADIA Pharmaceuticals (ACAD) is Neutral.

The composite score behind that read is -0.03, weighing +0.13 of bullish evidence against -0.47 bearish.

ACADIA Pharmaceuticals last closed at $19.78, +1.02% on the session.

Against the IVW growth benchmark the position is +0.22% over the forecast window.

The read is built from 15 underlying insights — 8 bullish and 7 bearish.

Agreement across those insights is 47%.

6 graded predictions for ACAD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks ACADIA Pharmaceuticals in the 88th percentile on valuation and the 88th percentile on return on equity, where 100 is best.

ACADIA Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $3.37B.

StockMap tracks ACADIA Pharmaceuticals as the 65th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite ACADIA Pharmaceuticals ranks 123rd of 381 in the group, against a group median of -0.08.